Great news for our NCDR Registries! The NCDR has secured its second multi-year Task Order contract with the FDA. Right now, we provide analyses of the diffusion of ICDs and carotid stents into the marketplace. The FDA recently asked us to respond to three new proposals: one for a study of atrial fibrillation ablation, one for a study of B-type Natriuretic Peptide and one for a study of lead safety. The FDA this week awarded us all three studies to be conducted over the next two years. This is an important signal of regulatory confidence in the outcomes-based evidence the NCDR can provide. Congratulations to all involved!

< Back to Listings